Five years later, 60% of patients are still in remission for the long-term effects of CAR-T therapy

Kymriah is the first CAR-T therapy to be approved by the FDA.
by targeting CD19 antigens on the surface of B cells, allowing modified CAR-T cells to destroy B lymphocytes in the blood.
the study, the researchers followed patients with diffuse large B-cell lymphoma (DLBCL) and recurring/refractic folytic lymphoma treated with Kymriah.
46% of the 24 DLBCL patients were in complete remission after five years.
71% of the 14 patients with relapsed/refratic folytic lymphoma were still in complete remission after 5 years.
also assessed the persistence of CAR-T cells in patients.
they found that 50 percent of patients with a remission period of more than one year did not have GENETIC modification of chised antigen receptors that expressed CD19 in their bodies after five years.
only one of the 18 patients who relapsed within a year of being treated with CAR-T cell therapy was genetically modified.
this result means that the loss of CAR-T cells may not be a common cause of therapeutic resistance.
"We found that the majority of patients who had a remission period of more than one year after receiving CAR-T cell therapy were still in remission after five years.
it's very exciting and shows the durability of this treatment. Dr. Elise A. Chong of the Department of Hematology/Oncology at the University of Pennsylvania School of Medicine, co-author of the
study, said, "For patients who do not respond to chemotherapy, this provides a treatment option that may lead to long-term remission."
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
a reference: s1 s penn-developed CAR T therapy show long-lasting remissions in non-hodgkin lymphoma. Retrieved February 18, 2021, from